THERAPEUTICS OF NEUROPSYCHIATRIC DISORDERS
Drug Discovery and Drug Screening
| Assay for Prediction of Analgesic Efficacy. Invention MCL 2668.0 |
Borsook | Contact McLean for more information |
| Methods for Identifying Anatomical and Molecular Targets for Analgesic Therapy Invention MCL 2669.0 |
Borsook | Contact McLean for more information |
| Glycine Transporter 1 Knockout Mice Invention MCL M01 |
Coyle | More details |
| Candidate Genes for Parkinson's Disease Invention MCL 2637.0 |
Isacson | Contact McLean for more information |
Novel Therapeutic Compounds
| Antidepressive Compounds and Uses
Thereof Invention MCL 2549.0 |
Beguin | More details |
| Compounds for the Treatment of Parkinson's Disease Invention MCL 2608.0 |
Kim | More details |
| Mixed Kappa/Mu Opioids and Uses Thereof Invention MCL 2245.0 (US Patent 7,271,173) |
Neumeyer | More details |
| N-Substituted Derivatives of Morphinan and Uses Thereof Invention MCL 1937.0 (US Patents 6,844,438 and 7,291,628) |
Neumeyer | More details |
Therapeutic Methods
| Method of Dopamine Inhibition using L-threo-methylphenidate. Invention MCL 1638.0 (US Patent 6,221,883) |
Baldessarini | More details |
| Dopamine D4 Receptor-Selective Antagonists as Treatment for Attention Deficit-Hyperactivity Disorder Invention MCL 1778.0 (US Patent 6,747,029) |
Baldessarini | More details |
| Treatment of Sequelae of Psychiatric Disorders Invention MCL 2725.0 |
Borsook | More details |
| Treatment of Depression Invention MCL 1793.0 (US Patent 6,528,518) |
Carlezon | More details |
| Methods for Promoting Neurogenesis Invention MCL 2782.0 |
Carlezon | More details |
| Treatment and Diagnosis of Diseases Characterized by Mitochondrial Dysfunction Invention MCL 3180.0 |
Cataldo | More details |
| Methods for Treatment of Mood Disorders Invention MCL 3088.0 |
Cohen | More details |
| Methods of Treating Pathological Gambling and other Compulsive Disorders Invention MCL 3268.0 |
Elman | More details |
| G-Substrate for Treatment and Prevention of Parkinson's Disease Invention MCL 3344.0 |
Isacson | More details |
| Rab3B for the Treatment and Prevention of Parkinson's Disease Invention MCL 3345.0 |
Isacson | More details |
| Compounds as Treatment for Depression or Dysthymia Invention MCL 168.0 |
Renshaw | More details |
| Treatment of Mental Conditions Including Depression Invention MCL 187.0 (US Patent 6,258,794) |
Renshaw | More details |
| Compounds for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) Invention MCL 1629.0 |
Renshaw | More details |
| Agents for Treatment of Cognitive Disorders Invention MCL 1811.0 |
Renshaw | More details |
| Treatments For Mental Conditions Including Depression Invention MCL 2002.0 |
Renshaw | More details |
| Combination Agents for Treatment of Cognitive Disorders Invention MCL 2688.0 |
Renshaw | More details |
| Improved Methods for the Treatment of Attentional Disorders Invention MCL 2645.0 |
Teicher | More details |
Stem Cell, Cell-Based Therapies
| Stem Cell Method for Treating Neurodegenerative Diseases Invention MCL 3182.0 |
Cataldo | More details |
| Dopaminergic Neurons Differentiated from Embryonic Cells for Treating Neurodegenerative Disorders Invention MCL 2127.0 |
Isacson | More details |
| Cell Sorting Codes for Purification of Neural Stem Cells and Stem Cell-Derived Neurons Invention MCL 3661.0 |
Isacson | More details |
| Neural Stem Cells Derived from Induced Pluripotent Stem Cells Invention MCL 3797.0 |
Isacson | More details |
| Cell-Specific Enhancer Domains for Neuronal Gene Expression Invention MCL 180.0, 1827.0 (US Patents 6,525,189 and 7,037,715) |
Kim | More details |